SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.
Cell
; 185(4): 603-613.e15, 2022 02 17.
Article
in En
| MEDLINE
| ID: mdl-35026152
ABSTRACT
SARS-CoV-2 mRNA vaccines induce robust anti-spike (S) antibody and CD4+ T cell responses. It is not yet clear whether vaccine-induced follicular helper CD4+ T (TFH) cell responses contribute to this outstanding immunogenicity. Using fine-needle aspiration of draining axillary lymph nodes from individuals who received the BNT162b2 mRNA vaccine, we evaluated the T cell receptor sequences and phenotype of lymph node TFH. Mining of the responding TFH T cell receptor repertoire revealed a strikingly immunodominant HLA-DPB1∗04-restricted response to S167-180 in individuals with this allele, which is among the most common HLA alleles in humans. Paired blood and lymph node specimens show that while circulating S-specific TFH cells peak one week after the second immunization, S-specific TFH persist at nearly constant frequencies for at least six months. Collectively, our results underscore the key role that robust TFH cell responses play in establishing long-term immunity by this efficacious human vaccine.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines, Synthetic
/
Vaccination
/
T Follicular Helper Cells
/
SARS-CoV-2
/
COVID-19
/
MRNA Vaccines
/
Immunity
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cell
Year:
2022
Type:
Article